Responses
Clinical and epidemiological research
Extended report
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.